The Drug-Induced Respiratory Disease Website and App

Certolizumab

(Certolizumab pegol). In patients exposed to both methotrexate and certolizumab who develop ILD, the assessment of drug causality (certolizumab vs. methotrexate) and hence which drug has to be withdrawn can be challenging

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)

I.x

Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.m

Sarcoid-like granulomatosis (endo-/extrathoracic)